[3-(4-Benzothiazol-2-yl-benzyl)-4-oxo-3,4-dihydro-phthalazin-1-yl]-acetic acid

ID: ALA414405

Chembl Id: CHEMBL414405

PubChem CID: 14810789

Max Phase: Preclinical

Molecular Formula: C24H17N3O3S

Molecular Weight: 427.49

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)Cc1nn(Cc2ccc(-c3nc4ccccc4s3)cc2)c(=O)c2ccccc12

Standard InChI:  InChI=1S/C24H17N3O3S/c28-22(29)13-20-17-5-1-2-6-18(17)24(30)27(26-20)14-15-9-11-16(12-10-15)23-25-19-7-3-4-8-21(19)31-23/h1-12H,13-14H2,(H,28,29)

Standard InChI Key:  PJXVPQIUWJKKNW-UHFFFAOYSA-N

Associated Targets(Human)

AKR1B1 Tclin Aldose reductase (1404 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Sord Sorbitol dehydrogenase (84 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 427.49Molecular Weight (Monoisotopic): 427.0991AlogP: 4.35#Rotatable Bonds: 5
Polar Surface Area: 85.08Molecular Species: ACIDHBA: 6HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 3.85CX Basic pKa: 2.03CX LogP: 4.74CX LogD: 1.60
Aromatic Rings: 5Heavy Atoms: 31QED Weighted: 0.45Np Likeness Score: -1.68

References

1. Mylari BL, Larson ER, Beyer TA, Zembrowski WJ, Aldinger CE, Dee MF, Siegel TW, Singleton DH..  (1991)  Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.,  34  (1): [PMID:1899452] [10.1021/jm00105a018]

Source